- Home
- BLKB vs XERS Comparison
BLKB vs XERS Comparison
Compare BLKB & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLKB | XERS |
|---|---|---|
| Founded | 1981 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BLKB | XERS |
|---|---|---|
| Price | $31.38 | $8.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $50.00 | $10.83 |
| AVG Volume (30 Days) | 842.1K | ★ 2.3M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.32 | 100.00 |
| EPS | ★ 0.67 | 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $6.26 | $34.37 |
| Revenue Next Year | $4.25 | $22.86 |
| P/E Ratio | ★ $47.04 | $860.50 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $25.58 | $4.87 |
| 52 Week High | $74.86 | $10.08 |
Technical Indicators
Market Signals| Indicator | BLKB | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 57.91 | 70.11 |
| Support Level | $28.88 | $6.86 |
| Resistance Level | $32.11 | $9.02 |
| Average True Range (ATR) | 1.45 | 0.35 |
| MACD | 0.41 | 0.00 |
| Stochastic Oscillator | 88.73 | 73.21 |
Price Performance
Historical ComparisonAbout BLKB Blackbaud Inc.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.